コンテンツへスキップ
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Studies
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 (Tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation & Resarch Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
Contact Us
Japanese site
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
MNOV: Positive Results for MN-166 in Phase 2 AUD Trial
Resarch Reports
2021.06.22
2025.10.16
MNOV: Phase 3 ALS Trial Ongoing
MNOV: Animal Trials Commence Testing MN-166 as an MCM
メニュー
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
検索
Resarch Reports
Resarch Reports
Resarch Reports
Resarch Reports
Resarch Reports
Resarch Reports
